The Valley of Death in the Bioeconomy: From Valley to Bridge

The path from a scientific idea to industrial application is rarely straightforward. In the bioeconomy in particular, there is often a critical phase between successful research and market launch – the so-called Valley of Death.

At this stage, resource requirements rise sharply, whilst uncertainties increase at the same time. Technologies must prove themselves on a larger scale for the first time, investment rises significantly, and business models must stand the test of time. It is precisely at this point that many innovations fail to reach the market – even though they are scientifically sound.

Contrary to popular belief, however, the Valley of Death is not an inevitable law of nature. Rather, it often arises where scaling is considered too late, demonstration infrastructure is lacking, or funding gaps emerge. Bioeconomic technologies are particularly affected by this, as they often require capital-intensive pilot and demonstration plants and scaling effects are difficult to predict. Processes that run stably in the laboratory can behave very differently on an industrial scale – both technically and economically.

The Valley of Death begins sooner than expected

In many projects, the ‘Valley of Death’ does not arise only at the demonstration plant stage, but much earlier. If scaling issues are only addressed after the laboratory phase, technical, economic and regulatory risks accumulate simultaneously. This complicates investment decisions and prolongs development times. Successful innovation processes therefore deliberately bring these issues to the fore: scalability, raw material availability, economic viability and market integration are already taken into account during the research phase.

This changes the nature of the development process. Instead of a steep drop-off, there is a gentler transition between research and application. The Valley of Death is not overcome – but narrowed.

What specifically helps to flatten the Valley of Death

Measures that mitigate technical and financial risks at an early stage are particularly effective:

• Consider scalability right from the research phase

• Share pilot and demonstration infrastructure

• Involve industry partners at an early stage

• Pursue phased scale-up strategies

• Develop market and business models in parallel

• Clarify regulatory requirements at an early stage

These approaches reduce uncertainty and provide a sound basis for investment decisions.

Financing remains the critical bottleneck

Despite technological advances, the demonstration phase remains the most challenging stage. First-of-a-kind plants are capital-intensive, yet there is a lack of reliable track records. Traditional funding schemes often end before this phase, whilst private investors are unwilling to bear the risk alone. New financing models can bridge this gap:

• Blended finance combining public funding and private capital

• Demonstration and scale-up funds

• Public-private partnerships

• Risk mitigation instruments

• Demand-driven funding models

Such instruments spread risk and facilitate the transition to industrial implementation.

From the valley to the bridge

Ultimately, the ‘Valley of Death’ refers less to a single problem than to a transitional phase within the innovation system. Where research, industry, funding and regulation operate in isolation from one another, a deep valley emerges. If these elements are linked at an early stage, a bridge is formed rather than a precipice.

This is particularly crucial for the bioeconomy. The transition to sustainable production systems depends not only on new ideas, but also on whether these can be successfully scaled up. The Valley of Death remains a challenge, but it is not an inevitable one. With an early-stage scaling strategy, suitable infrastructure and coordinated funding, the most critical phase of innovation can be significantly smoothed out – and bioeconomic solutions can reach the market more quickly.